Aceminid Dosing Guide + Maximum Dose, Adjustments

Asciminib is a kinase inhibitor used to treat certain types of leukemia.

For Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+) in the chronic phase (CP) For adult patients with CML who have been previously treated with two or more tyrosine kinase inhibitors (TKIs), the recommended dose of aciminib is 80 mg orally once daily or 40 mg in two divided doses per day. For Ph+ CML-CP patients with the T315I mutation, the recommended dose is higher, 200 mg taken orally twice daily.

Normally, the maximum daily dose of aceminib is 80mg, whether taken as a single dose or in two divided doses. For patients with the T315I mutation, the maximum daily dose may be increased to 400 mg.

If a patient cannot tolerate a dose of 80mg per day, doctors may recommend reducing the dose to 40mg once a day or 20mg twice a day for patients who have been previously treated with two or more TKIs. For patients with the T315I mutation who cannot tolerate a dose of 400 mg per day, a first dose reduction of 80 mg twice daily (a total of 160 mg) may be considered.

If a patient continues to be unable to tolerate aceminib despite dose adjustments, the drug may need to be permanently discontinued.

Patients should avoid eating at least2 hours before and 1 hours after taking aceminib. Acemini tablets should be swallowed whole and should not be broken, crushed, or chewed. If a dose is missed, skip the dose if more than 12 hours have passed for the once-daily dosing regimen or if more than 6 hours have passed for the twice-daily dosing regimen.